Ayala Pharmaceuticals Inc (ADXS) - News Archive

Showing 2 of 2 results.

Completing Patient Enrollments: A Milestone for Ayala Pharmaceuticals' Promising Desmoid Tumor Study

Immunome Recognizes Completion of Patient Enrollment in Ayala Pharmaceuticals Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid TumorsBOTHELL, Wash. - Immunome, Inc. recently acknowledged the announcement made by Ayala...

Feb 20, 2024 • Major Pharmaceutical Preparations Industry Product Service News OTCB

Immunome Acquires AL102 and AL101, Groundbreaking Drug Candidates for the Treatment of Desmoid Tumors, from Ayala Pharmaceuticals.

Immunome Acquires AL102, a Promising Phase 3 Asset for the Treatment of Desmoid Tumors, from Ayala PharmaceuticalsIn a significant development in the field of targeted cancer therapies, Immunome, Inc. (Nasdaq: IMNM), a...

Feb 6, 2024 • Major Pharmaceutical Preparations Industry Product Service News OTCB